Tower Research Capital LLC TRC Sells 4,872 Shares of Medifast, Inc. (NYSE:MED)

Tower Research Capital LLC TRC decreased its holdings in Medifast, Inc. (NYSE:MED) by 70.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,068 shares of the specialty retailer’s stock after selling 4,872 shares during the period. Tower Research Capital LLC TRC’s holdings in Medifast were worth $36,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Marshall Wace LLP bought a new position in shares of Medifast in the 4th quarter worth $1,836,000. Barclays PLC lifted its position in Medifast by 15.1% during the fourth quarter. Barclays PLC now owns 16,194 shares of the specialty retailer’s stock valued at $285,000 after purchasing an additional 2,127 shares during the period. Federated Hermes Inc. grew its holdings in Medifast by 28.8% during the fourth quarter. Federated Hermes Inc. now owns 279,473 shares of the specialty retailer’s stock worth $4,924,000 after acquiring an additional 62,574 shares during the period. Wells Fargo & Company MN boosted its holdings in Medifast by 23.5% during the fourth quarter. Wells Fargo & Company MN now owns 6,459 shares of the specialty retailer’s stock worth $114,000 after buying an additional 1,227 shares in the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of Medifast during the 4th quarter valued at about $577,000. Institutional investors own 95.51% of the company’s stock.

Analyst Upgrades and Downgrades

MED has been the topic of a number of research reports. DA Davidson decreased their price target on shares of Medifast from $17.00 to $16.50 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. StockNews.com upgraded shares of Medifast from a “hold” rating to a “buy” rating in a research report on Thursday, May 1st.

Medifast Trading Up 0.5%

Medifast stock opened at $12.78 on Thursday. The firm has a market capitalization of $140.46 million, a P/E ratio of 71.00 and a beta of 0.96. The stock’s fifty day simple moving average is $13.18 and its 200-day simple moving average is $15.73. Medifast, Inc. has a twelve month low of $11.57 and a twelve month high of $26.85.

Medifast (NYSE:MED) last announced its quarterly earnings results on Monday, April 28th. The specialty retailer reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). Medifast had a net margin of 0.35% and a return on equity of 10.64%. The company had revenue of $115.73 million during the quarter, compared to analysts’ expectations of $114.85 million. Sell-side analysts predict that Medifast, Inc. will post 0.51 earnings per share for the current year.

Medifast Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.